Johnson & Johnson: UBS maintains Buy, raises PT to $190 from $180.

Johnson & Johnson: UBS maintains Buy, raises PT to $190 from $180.

Johnson & Johnson (NYSE: JNJ) has seen its stock price target raised by UBS analyst Danielle Antalffy to $190 from $180, maintaining a Buy rating. This move follows the company's recent upbeat earnings report and updated guidance for fiscal year 2025 [2].

The pharmaceutical giant reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year over year, but beating the consensus estimate of $2.68. Sales of $23.74 billion, up 5.8% year over year, also exceeded expectations [2].

Johnson & Johnson revised its fiscal year 2025 guidance upward, expecting adjusted earnings of $10.80-$10.90, compared to the previous guidance of $10.50-$10.70. Sales guidance was also raised from $91 billion-$91.8 billion to $93.2 billion-$93.6 billion [2].

The company's stock price gained 6.2% to close at $164.78 on Wednesday following the earnings announcement [2].

UBS's new price target is based on a sum-of-the-parts analysis of the company's business segments, reflecting the positive outlook for the healthcare giant's growth prospects and strong financial health [1].

References:
[1] https://www.investing.com/news/analyst-ratings/johnson--johnson-stock-price-target-raised-by-stifel-to-165-from-155-93CH-4138403
[2] https://www.benzinga.com/news/25/07/46466890/johnson-johnson-analysts-raise-their-forecasts-after-upbeat-earnings